New method could fast-track existing drugs as novel treatments for depression

February 17, 2017
New method could fast-track existing drugs as novel treatments for depression

Research from King's College London reveals a new method of repurposing existing drugs as novel treatments for depression, using laboratory studies of brain cells.

The results reflect a growing movement towards repurposing drugs that have been developed for one condition to tackle another. This approach effectively bypasses the discovery phase of development, which could save significant time and money in finding effective treatments.

Finding ways to fast-track the discovery of new antidepressants is crucial as around half of all people diagnosed with depression do not respond to first-line treatments.

Published today in the Journal of Psychopharmacology, this new study measured the effects of two types of antidepressant on levels of gene expression (activity) in in the hippocampus. Previous research has shown that hippocampal stem cells are altered in depressed patients and are the catalyst for the action of some antidepressants.

Using a method known as 'connectivity mapping', the researchers identified gene activity signatures unique to antidepressants. They then searched for the same or very similar signatures in a database of more than 1,300 medications that are currently used to treat a wide range of illnesses.

This process identified two drugs with the same signatures as antidepressants tested in the first part of their study, which means they could have the potential to be repurposed as treatments for depression. The two drugs identified using this process will now be tested to discover whether they are clinically effective treatments for depression.

Dr Sandrine Thuret, corresponding and joint senior author of the study, from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London, said: 'Thanks to advances in technology we're now using to uncover molecular similarities between diseases, allowing researchers to identify drugs already used for one disorder that have the potential to be repurposed as treatments for another illness.'

Dr Timothy Powell, first author of the study, also from the IoPPN at King's College London, said: 'These results are particularly exciting as they show the potential of this method to vastly accelerate or even bypass the discovery phase of . This would have clear economic benefits and save precious time in finding a treatment that works for each individual. The next step will be trying to further validate whether the compounds we identified have a clinically meaningful effect on depression symptoms.'

Dr Gerome Breen, joint senior author from the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and the IoPPN, King's College London, said: 'The ability of genomics to provide tools for drug discovery has been utilised for a long time in cancer research, in particular. Now we have shown that this method can also work for mental health, providing valuable information about new drugs that could be investigated in .'

Explore further: Blood test to personalize depression treatment for the first time

More information: Timothy R Powell et al. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its application in drug repositioning, Journal of Psychopharmacology (2017). DOI: 10.1177/0269881117691467

Related Stories

Blood test to personalize depression treatment for the first time

June 6, 2016
Scientists at King's College London have developed a blood test that accurately and reliably predicts whether depressed patients will respond to common antidepressants, which could herald a new era of personalised treatment ...

Researchers discover 'molecular switch' that causes auto-immune diseases

February 16, 2017
Wednesday February 15, London: The discovery of the 'molecular switch' that causes inflammatory bowel disease (IBD) and Celiac disease, could lead to more effective new treatments for these life-changing auto-immune conditions, ...

Antidepressants induce resilience and reverse susceptibility

February 2, 2017
When they work, antidepressant medications may take weeks or months to alleviate symptoms of depression. Progress in developing new and more effective antidepressant treatments has been limited, though a new study published ...

Discovery of pathway leading to depression reveals new drug targets

December 6, 2012
Scientists have identified the key molecular pathway leading to depression, revealing potential new targets for drug discovery, according to research led by King's College London's Institute of Psychiatry. The study, published ...

Antidepressants beneficial for women with postnatal depression

May 19, 2015
Antidepressants are associated with better rates of treatment response and remission for women with postnatal depression, when compared to a placebo, according to a new systematic review by the Institute of Psychiatry, Psychology ...

Study reveals why some depressed patients have blood inflammation

May 5, 2016
A new King's College London study reveals why some - but not all - people have depression that appears to be caused by blood inflammation.

Recommended for you

Researchers find way to convert bad body fat into good fat

September 19, 2017
There's good fat and bad fat in our bodies. The good fat helps burn calories, while the bad fat hoards calories, contributing to weight gain and obesity. Now, new research at Washington University School of Medicine in St. ...

New model may help science overcome the brain's fortress-like barrier

September 19, 2017
Scientists have helped provide a way to better understand how to enable drugs to enter the brain and how cancer cells make it past the blood brain barrier.

Cell-based therapy success could be boosted by new antioxidant

September 19, 2017
Cell therapies being developed to treat a range of conditions could be improved by a chemical compound that aids their survival, research suggests.

Study suggests epilepsy drug can be used to treat form of dwarfism

September 19, 2017
A drug used to treat conditions such as epilepsy has been shown in lab tests at The University of Manchester to significantly improve bone growth impaired by a form of dwarfism.

Research predicts how patients are likely to respond to DNA drugs

September 19, 2017
Research carried out by academics at Northumbria University, Newcastle could lead to improvements in treating patients with diseases caused by mutations in genes, such as cancer, cystic fibrosis and potentially up to 6,000 ...

Urine output to disease: Study sheds light on the importance of hormone quality control

September 18, 2017
The discovery of a puddle of mouse urine seems like a strange scientific "eureka" moment.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.